Linked Life Data

7528962

Source:http://linkedlifedata.com/resource/pubmed/id/7528962

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1995-2-1
pubmed:abstractText
Platinum derivatives are known as the most effective cytostatic agents in ovarian carcinoma. The steep dose-response curves described by Hryniuk and Levin [5] make them the ideal substances for dose escalation. We treated patients with advanced ovarian carcinoma with dose intensified carboplatinmonotherapy six times at AUC 5 (= +/- 400 mg/m2 in patients with normal renal function). Dose intensification was not done by increasing single doses, but by shortening the intervals between therapies (23, 21, 17, 14 days). In order to prevent leucopenia G-CSF was administered at a dose of 5 micrograms/kg s.c. Besides mild emesis no extramedullary toxicity especially no alopezia was documented. Up to an interval of 17 days therapy was safe; no thrombocytopenia < 49,000 x 10(6)/L and no leucopenia < 1000 x 10(6) was observed. With the intention to arrive at a 14-day interval and to attain further dose escalation we will treat future patients with a slightly reduced dose of carboplatin (AUC 4) in combination with escalating doses of cis-platinum, which is known for its low myelotoxicity.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0044-4197
pubmed:author
pubmed:issnType
Print
pubmed:volume
116
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
549-54
pubmed:dateRevised
2008-2-11
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
[Dose intensified carboplatin monotherapy in advanced ovarian cancer].
pubmed:affiliation
Universitätsfrauenklinik Düsseldorf.
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract, Clinical Trial, Phase II, Clinical Trial, Phase I